It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked ...

AbbVie's longtime CEO, Richard Gonzalez, who held his position since the business spun off from Abbott Laboratories in 2013, ...

AbbVie is also looking at inorganic growth. After its acquisition of Allergan in 2020, it acquired ImmunoGen for $10.1 billion this year, giving it rights to Elahere — an ovarian cancer ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cancer stocks.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $209.00. The company’s shares closed ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

Among some other larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest ...

The company recently strengthened its oncology presence by acquiring ImmunoGen for $10.1 billion ... future growth once the Humira decline stabilizes. CFRA maintains a "buy" rating on AbbVie with a ...